Non Infectious Macular Edema Treatment Market

Global Market Study on Non-infectious Macular Edema Treatment: Companies to Launch Biosimilars of First Anti-VEGF Lucentis by 2020

Non-infectious Macular Edema Treatment Market Segmented By Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics Drug with Non-infectious Uveitic Macular Edema, Diabetic Macular Edema, Retinal Vein Occlusion with Macular Edema Indication by Oral, Parenteral, Topical Route of Administration

  • May-2018
  • PMRREP22984
  • 323 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Study unveils Corticosteroids as the fastest growing treatment for non-infectious macular edema in the global market

The global non-infectious macular edema treatment market is propelled with the increase in diabetes related complications and awareness in many regions towards eye-related diseases. The demand has an immediate impact on the increase in treatment options available for macular edema. The market comprises drug options like Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and others. Anti-VEGF is projected to continue holding the highest market share in the global market during the period of forecast.

However, the Anti-VEGF market is expected to witness a steady decline in use with the growing awareness about various side-effects associated with this drug. Systemic immunomodulatory treatment will serve to diminish reliance on anti-VEGF. Corticosteroids are also expected to witness an exceptional rise in demand in the coming years. The Corticosteroids market is expected to rise at a stellar growth rate of 8.3% during the forecast period.

non infectious macular edema treatment

Find Out More about the Report Coverage

Companies

Company Profiles

  • Allergan, Plc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • F. Hoffman - La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Valeant Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Clearside Biomedical, Inc.
  • Others.

Approval of Intravitreal Implants and use of Immunosuppressants in the treatment of macular edema to trigger the growth of the market

Intravitreal Implants have been recently approved for the treatment of macular edema. Launch of three new products in 2014 viz., Eylea, Ozurdex and Iluvien, has led to the increased adoption of intravitreal medications in North America. The use of intravitreally injected medications was less common in North America and European countries as laser photocoagulation was the primary treatment before the launch of Lucentis in 2012.

This increase in the adoption of Intravitreal therapies is a result of the launch of low dose high efficacy corticosteroid implants for Intravitreal use. Uptake of Intravitreal implants is increasing among patients, thus boosting the global demand for macular edema treatment.

Immunosuppressant therapies are widely utilized coupled with corticosteroids. These are generally added to the corticosteroid regimen to eliminate the need for high doses of systemic steroids, or used alone as steroid-sparing agents in situations where steroids cannot be tolerated.

For e.g., the three immunomodulators methotrexate (Rheumatrex), azathioprine (Imuran) and mycophenolate mofetil (MMF, Cellcept) are more effective in achieving disease quiescence and are well-tolerated by patients. These work as an efficient treatment type in the cure of non-infectious macular edema thereby proliferating demand in the global market.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Availability of alternative treatment options and off-label drug use expected to hinder the growth of the global macular edema market

In several cases, patients and ophthalmologists prefer alternative treatments to anti-VEGF and corticosteroids to treat the various types of macular edema in patients. Anti-VEGF and corticosteroids require repeated injection of costly drugs. Majority of patients do not comply with the treatment schedule and tend to miss injections. If patients are left untreated for more than six months, DME causes irreversible damage to the photoreceptor and permanent loss of vision. This makes the population look for alternative options in the market.

Similarly, there are also many counterfeit and off label drugs available in the global market. The launch of biosimilars for some of the blockbuster anti-VEGF agents is also expected to decrease overall market opportunity for the growth of branded and patented drugs throughout the world.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

Market Taxonomy

Drug Type
  • Anti-VEGF
  • Corticosteroids
  • Immunosuppressant
  • Biologics
  • Others
Indication
  • Non-infectious Uveitic Macular Edema
  • Diabetic Macular Edema
  • Retinal Vein Occlusion with Macular Edema
Route of Administration
  • Oral
  • Parenteral
  • Topical
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Latin America
  • Europe
  • Japan
  • MEA
  • APAC

Explore Persistence Market Research’s expertise in promulgation of the business !

Media Release

Recommendations

Renal Anemia Treatment Market

The report on Renal Anemia Treatment further projects significant growth potential with average year-on-year growth rate pegged at 7.5% over the period of 2018-2026..

Sarcopenia Treatment Market

Sarcopenia Treatment Market is projected to reach US$ 3,302.0 Mn by the end of 2026 and grow at a CAGR of 4.2% during the forecast period..

Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market is largely dominated by large vendors who are competing on the basis of market penetration and distribution.Companies, such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo Pharmaceuticals Inc., hold more than 50% revenue share in the global post herpetic neuralgia treatment market..

Compounding Pharmacies Market

Compounding Pharmacies Market is expected to expand around 2.4X, reflecting a CAGR of 8.3% over the forecast period (2021-2031)..

Our Clients

Our Clients